Skip to content

Psychedelic-assisted therapy: all studies

Page 43 of 294: studies 421 to 430 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy

medRxiv April 19, 2023 Jennifer Bennett, Michael D. Blough, Ian Mitchell et al. 3 citations preprint

Abstract This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin, are increasingly being recognized as a successful treatment option for many mental health concerns. In order to decrease the risks associated with its clinical use, more data is required regarding its physiological effects in healthy individuals....

Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression: A Patient With Lifelong Self-Doubt and Self-Criticism.

The Journal of Clinical Psychiatry April 5, 2023 Albert Yeung, Guy Sapirstein, Laura D Crain et al.

Although consensus in the field is lacking, the most common definition for treatment-resistant depression (TRD) requires a minimum of 2 prior treatment failures with confirmed adequate dose and duration. This article presents a clinical example of TRD in a patient with a long history of depression and inadequate response to treatment. The prominent feature is the patient's persistent...

MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail.

Australian & New Zealand Journal of Psychiatry April 1, 2023 Gillinder Bedi, Susan M Cotton, Alexandre A. Guerin et al. 17 citations

Recent years have seen escalating media, public and scientific interest in psychedelic medicine. Australia and New Zealand have been late to this research; however, in the past 2 years, rapid developments suggest that this is changing. Here, we argue for the need to critically review existing evidence in this field to guide future directions. We focus on...

IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.

Pharmacological Research April 1, 2023 Deborah C. Mash 37 citations

Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors. Ibogaine has a very long history of ethnobotanical use in low doses to combat fatigue, hunger and thirst and, in high doses as a sacrament in African ritual contexts. In the 1960's, American and European self-help groups provided public testimonials that a single...

On the need for metaphysics in psychedelic therapy and research

Frontiers in Psychology March 31, 2023 Peter Sjöstedt-hughes 54 citations

The essential proposal of this text is that psychedelic-induced metaphysical experiences should be integrated and evaluated with recourse to metaphysics. It will be argued that there is a potential extra benefit to patients in psychedelic-assisted therapy if they are provided with an optional, additional, and intelligible schema and discussion of metaphysical options at the integrative phase of...

DOI: 10.3389/fpsyg.2023.1128589 (opens in new tab) Mysticism Metaphysics Epistemology Argument complex analysis +2

View, meditation, action: A Tibetan framework to inform psychedelic-assisted therapy

Journal of Psychedelic Studies March 28, 2023 Colin H. Simonds 6 citations

Abstract Whether occasioned through careful, consistent meditative practice or through quicker means like the ritual ingestion of psilocybin or ayahuasca, global contemplative practices have established effective systems of implementing, directing, and integrating the very kinds of non-ordinary experiences central to psychedelic use. However, contemplative traditions are largely absent from the...

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder

Frontiers in Psychiatry March 14, 2023 Jonathan Brett, Elizabeth Knock, Paul Liknaitzky et al. 16 citations

Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted...

DOI: 10.3389/fpsyt.2023.1123424 (opens in new tab) Psilocybin Methamphetamine Psychotherapist Hallucinogen +2

Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.

Journal of Bioethical Inquiry March 1, 2023 Lauren S Otterman 9 citations

Eating disorders are debilitating diseases that have twin impacts on the body and mind and are associated with a number of physiological and psychological comorbidities (Blinder, Cumella, and Sanathara 2006; Casiero and Frishman 2006), including increased suicide risk (Arcelus et al. 2011; Lipson and Sonneville 2020). In addition, eating disorders are growing in prevalence (Gilmache et al....